An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression

Summary

The purpose of the study is to evaluate the efficacy and safety of saredutant (or SR48968C) in patients with depression. The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in patients with depression. The secondary objectives are to evaluate the safety of saredutant, to evaluate the efficacy of saredutant on disability and quality of life in patients with depression, and to evaluate blood levels of saredutant.

Timeline

Start

2005-04

Primary completion

2006-10

Completion

2006-10

Drugs

Indications